Profile data is unavailable for this security.
About the company
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
- Revenue in USD (TTM)5.64m
- Net income in USD-9.25m
- Incorporated2013
- Employees18.00
- LocationBellerophon Therapeutics Inc184 Liberty Corner Road, Suite 302WARREN 07059United StatesUSA
- Phone+1 (908) 574-4770
- Fax+1 (302) 636-5454
- Websitehttp://www.bellerophon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 599.73k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Emo Capital Corp | -100.00bn | -100.00bn | 649.40k | 0.00 | -- | -- | -- | -- | -- | -- | -- | -0.0017 | -- | -- | -- | -- | -- | -7,495.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -138.44 | -- | -- | -- |
| Endonovo Therapeutics Inc | 255.72k | -4.40m | 693.55k | 0.00 | -- | -- | -- | 2.71 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
| Cannabis Suisse Corp | 30.00k | -254.75k | 703.08k | -- | -- | -- | -- | 23.44 | -0.0057 | -0.0057 | 0.0007 | -0.0103 | 0.0675 | -- | -- | -- | -57.35 | -149.71 | -238.71 | -- | 8.37 | -39.11 | -849.17 | -427.20 | -- | -13.57 | 3.38 | -- | 28.70 | 9.00 | -87.10 | -- | -- | -- |
| Health Advance Inc | -100.00bn | -100.00bn | 743.79k | 3.00 | -- | 0.1891 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
| Bellerophon Therapeutics Inc | 5.64m | -9.25m | 764.54k | 18.00 | -- | 0.2054 | -- | 0.1356 | -0.8353 | -0.8353 | 0.5054 | 0.3044 | 0.6414 | -- | -- | 313,333.30 | -105.23 | -55.57 | -165.94 | -77.33 | -- | -- | -164.06 | -- | -- | -- | 0.00 | -- | -- | -- | -11.69 | -- | -- | -- |
| Capstone Holding Corp | 0.00 | -358.00k | 819.57k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
| Sunshine Biopharma Inc | 24.09m | -4.51m | 832.92k | 44.00 | -- | 0.0111 | -- | 0.0346 | -19.07 | -19.07 | 99.47 | 75.68 | 0.8515 | 3.49 | 10.79 | 547,563.40 | -15.92 | -101.52 | -20.43 | -137.04 | 34.61 | 35.47 | -18.70 | -165.33 | 3.45 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
| Kaya Holdings Inc | 196.30k | 1.61m | 842.57k | 2.00 | 0.5426 | -- | 0.5112 | 4.29 | 0.07 | 0.07 | 0.0038 | -0.6222 | 0.3707 | 7.66 | -- | 98,150.00 | 309.03 | 28.68 | -- | -- | 58.56 | 65.75 | 833.66 | 66.12 | 0.0118 | -- | -- | 0.00 | -71.36 | -29.62 | 145.01 | -19.45 | -- | -- |
| International Stem Cell Corp | 7.79m | -131.00k | 872.48k | 29.00 | -- | -- | 13.85 | 0.112 | -0.0164 | -0.0164 | 0.9731 | 0.0141 | 1.48 | 2.40 | 11.79 | 268,586.20 | -2.49 | -29.22 | -24.76 | -73.82 | 59.16 | 59.49 | -1.68 | -21.01 | 0.4673 | -4.77 | 0.9684 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
| Comera Life Sciences Holdings Inc | 1.00m | -9.35m | 922.13k | 12.00 | -- | -- | -- | 0.9218 | -0.4901 | -0.4901 | 0.0512 | 0.0033 | 0.2498 | -- | 5.08 | 83,367.50 | -224.98 | -- | -1,094.30 | -- | 73.52 | -- | -900.55 | -- | -- | -- | 0.00 | -- | 97.95 | -- | -237.10 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Lepercq, de Neuflize Asset Management LLCas of 18 Dec 2023 | 1.03m | 8.39% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 4.52k | 0.04% |
| Janus Henderson Investors US LLCas of 30 Jun 2023 | 0.00 | 0.00% |
| Tower Research Capital LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| Group One Trading LPas of 31 Dec 2023 | 0.00 | 0.00% |
| Citadel Securities LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| U.S. Bank NA (Cincinnati Ohio Investment Management)as of 31 Dec 2023 | 0.00 | 0.00% |
| American Portfolios Advisors, Inc.as of 31 Dec 2023 | 0.00 | 0.00% |
| Wells Fargo Clearing Services LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 0.00 | 0.00% |
